Oral-IV Probe Comparisons for First-Pass Localization

Why Compare Oral and Intravenous Probes?

An oral drug exposure can change during a drug-drug interaction (DDI) for at least two broad reasons: systemic clearance may change after drug reaches the circulation, or the fraction of the oral dose reaching the circulation may change. Oral AUC alone combines these effects. An intravenous (IV) probe provides a way to estimate systemic clearance independently of oral absorption and first-pass availability. Comparing dose-normalized oral and IV exposures can therefore separate a clearance contribution from a change in total oral availability.

The distinction is useful when a PBPK interpretation asks whether an interaction is consistent with altered disposition in the systemic circulation or with altered processes before the drug reaches it. However, an oral-IV comparison does not, by itself, uniquely identify the intestine as the site of an availability change. Oral availability includes absorption and both intestinal and hepatic first-pass escape.

The Oral-IV Comparison

Let condition 0 denote a control condition and condition 1 denote the condition with the perpetrator drug. For each condition, use AUC for the same analyte, ordinarily unchanged parent drug, and divide by the administered dose for that route. Under linear pharmacokinetics and complete AUC measurement, the IV and oral relationships are:

The first relationship follows because an IV dose enters the systemic circulation directly. The second includes the fraction \(F\) that reaches the circulation. Define the dose-normalized exposure ratios as condition 1 divided by condition 0:

The IV ratio estimates the reciprocal change in clearance, while dividing the oral ratio by the IV ratio removes that clearance contribution. The resulting ratio estimates the change in total oral availability:

Derivation and Assumptions

The result can be derived directly from the AUC relationships. For condition \(j\), where \(j\) is 0 or 1, the dose-normalized IV AUC is \(1/CL_j\), so:

For the oral route, the dose-normalized AUC is \(F_j/CL_j\). Thus:

Rearranging gives \(F_1/F_0=R_{\mathrm{oral}}/R_{\mathrm{IV}}\). This is a ratio of availabilities, not an absolute estimate of either condition’s availability unless additional information is available. The derivation assumes linear pharmacokinetics over the doses used, so that AUC is proportional to dose and \(CL\) is not dose-dependent. It also assumes that the same systemic clearance applies to drug reaching the circulation by either route, that the IV and oral measurements refer to the same parent analyte, and that AUC is measured over a sufficiently complete interval. Conditions should be sufficiently comparable that the ratios reflect the interaction rather than unrelated differences in participants or study conduct.

For paired data, calculate each participant’s dose-normalized ratios and then summarize the within-participant comparisons. A common summary is the geometric mean ratio: calculate log ratios for each participant, average those log ratios, and exponentiate the average. This respects the multiplicative form of exposure ratios. The algebra above applies to the underlying ratios; a ratio of group arithmetic means need not equal a mean of paired ratios.

What the Comparison Can—and Cannot—Localize

The quantity \(F_1/F_0\) concerns total oral availability. Since \(F=F_aF_gF_h\), its relative change can reflect altered absorption, intestinal first-pass escape, hepatic first-pass escape, or a combination. The oral-IV comparison separates the overall availability contribution from systemic clearance, but does not separate the components of \(F\).

Attribution to an intestinal first-pass change therefore requires further justification. For example, if absorption and hepatic first-pass availability can reasonably be treated as unchanged between conditions, then a relative change in total \(F\) is consistent with a change in \(F_g\). In PBPK analysis, this attribution may instead depend on additional mechanistic evidence and a model that represents gut and hepatic processes separately. Without such evidence or assumptions, describing the result as a change in intestinal availability is more specific than the data support.

A comparison of oral exposures alone is the main alternative when IV data are unavailable, but it cannot separate \(F\) from \(CL\) using AUC ratios alone. An IV-only comparison can identify a change in systemic clearance under the assumptions above, but says nothing directly about oral availability. Oral-IV pairing offers both pieces of information, at the cost of requiring IV probe administration, adequate sampling, and compatible route-specific measurements.

Diagnostics, Failure Modes, and Limitations

Before interpreting the quotient of ratios, check whether the data and design support the equations. Dose-normalize both routes even when doses appear similar; otherwise unequal doses can be mistaken for a change in exposure. Confirm that the AUCs refer to the same analyte and are estimated comparably. Incomplete terminal sampling or substantial extrapolation can distort AUC, and route-specific sampling problems can make the oral and IV ratios incomparable.

• Nonlinear pharmacokinetics: If AUC is not proportional to dose, dose normalization does not produce a common \(F/CL\) or \(1/CL\). A dose-dependent process, such as saturable elimination or absorption, can invalidate the ratio interpretation.
• Clearance not comparable across routes: The derivation requires the same systemic clearance for drug entering from either route. If the conditions change during sampling or the route measurements do not represent comparable systemic disposition, the IV ratio may not correct the oral ratio as intended.
• Misreading an oral-only increase: An increase in oral AUC does not, on its own, prove increased availability. Lower clearance also increases oral AUC.
• Over-localizing the result: A difference between \(R_{\mathrm{oral}}\) and \(R_{\mathrm{IV}}\) points to a change in total \(F\) under the model; it does not identify intestinal rather than hepatic first-pass change, or distinguish either from altered absorption.
• Uncertain estimates: Observed ratios are estimates. When their uncertainty is large, apparent agreement or disagreement should not be treated as definitive evidence of unchanged or changed availability.

The design also has practical limits. An IV probe may be difficult to administer or may not be available in a suitable formulation. Route comparisons can require more sampling and careful alignment of conditions. Finally, a relative availability ratio does not reveal absolute \(F\) unless at least one condition’s absolute availability is known or can be estimated. These constraints matter when deciding whether oral-IV data can answer the specific mechanistic question of interest.